```html

Exostoses (Osteochondroma) – Comprehensive Medical Guide

Overview

Osteochondroma, also known as an exostosis, is a benign bone tumor that presents as a cartilage‑capped bony outgrowth arising from the surface of a bone, most often near the growth plates of long bones (e.g., femur, tibia, humerus). While the lesion itself is non‑cancerous, it can cause pain, functional limitation, or, rarely, malignant transformation into chondrosarcoma.

Who it affects: The condition usually appears in children and adolescents during the growth phase. About 70–80 % of cases are diagnosed before age 20, and the lesions often stop growing once skeletal maturity is reached.<sup>[1] Mayo Clinic</sup>

Prevalence: Osteochondromas are the most common benign bone tumor, accounting for 30–40 % of all benign bone neoplasms and 10–15 % of all bone tumors. Population‑based studies estimate a prevalence of roughly 1–2 per 100,000 people, with a slightly higher occurrence in males (male‑to‑female ratio ≈ 1.5:1).<sup>[2] WHO Classification of Tumours</sup>

Symptoms

Many osteochondromas are asymptomatic and discovered incidentally on X‑ray. When symptoms occur, they fall into several categories:

• Pain – dull ache or sharp pain at the site, often worsened by activity or pressure.
• Swelling or a palpable lump – a hard, usually painless bump that may become tender if a bursa forms over it.
• Limited range of motion – especially when the lesion is near a joint (e.g., shoulder, knee).
• Neurologic symptoms – tingling, numbness, or weakness if the exostosis compresses a nerve (most common in the forearm or pelvis).
• Vascular compromise – rare; may present as diminished pulses or swelling from venous obstruction.
• Fracture of the stalk – can cause sudden, severe pain, often after a minor trauma.
• Skin irritation or ulceration – when the growth rubs against clothing or footwear.
• Malignant transformation signs – rapid growth after skeletal maturity, new onset pain, or a lesion >2 cm thick on imaging may suggest chondrosarcoma.

Causes and Risk Factors

Genetic Causes

• Hereditary Multiple Exostoses (HME) – an autosomal dominant disorder caused by mutations in the EXT1 or EXT2 genes, which encode enzymes important for heparan sulfate synthesis. HME patients develop 10–30 lesions on average and are at higher risk for complications and malignant change.

Non‑Genetic (Sporadic) Causes

• Isolated (solitary) osteochondroma – the vast majority of cases occur without a known genetic mutation; the exact trigger is unknown, but it is thought to arise from a developmental error during endochondral ossification.

Risk Factors

• Male sex (approximately 60 % of cases).
• Family history of HME.
• Early onset of growth spurts (rapid skeletal growth may unmask lesions).
• Previous trauma to the affected region – occasionally reported, though not proven causative.

Diagnosis

Clinical Examination

A clinician will first look for a hard, non‑compressible mass that is usually attached to the underlying bone. Mobility of the lesion is limited; it does not shift independently of the bone.

Imaging Studies

• Plain Radiography (X‑ray) – first‑line. Shows a bony protrusion with continuity of the cortical and medullary bone with the parent bone. A thin layer of cartilage may not be visible.
• Computed Tomography (CT) – provides detailed bone architecture, useful for surgically complex locations (pelvis, spine).
• Magnetic Resonance Imaging (MRI) – best for evaluating the cartilage cap thickness and surrounding soft‑tissue involvement. A cap >2 cm in adults raises suspicion for malignant transformation.
• Ultrasound – can detect a superficial cartilaginous cap and associated bursitis.

Laboratory Tests

Routine blood work is usually normal. In cases where malignancy is suspected, a full metabolic panel and alkaline phosphatase may be ordered, but they are not diagnostic.

Histopathology

If the lesion is removed, pathological examination confirms diagnosis and evaluates for atypia. The hallmark is a cartilage cap with orderly endochondral ossification.

Treatment Options

Observation (Watchful Waiting)

Most solitary osteochondromas that are painless and not functionally limiting can be monitored with yearly clinical exams and periodic imaging until skeletal maturity.

Surgical Excision

• Indications – pain, functional impairment, neurovascular compromise, rapid growth after age 20, or suspicion of malignant change.
• Procedure – removal of the bony stalk and cartilage cap, often through a small incision. In complex sites (e.g., pelvis, spine), a multidisciplinary team may be needed.
• Outcomes – recurrence is low (<2 %) when the entire cartilage cap is removed. Complications include infection, nerve injury, and fracture.

Medications & Symptomatic Relief

• Analgesics – acetaminophen or NSAIDs for mild to moderate pain.
• Physical therapy – to maintain joint range of motion and muscle strength around the lesion.
• Corticosteroid injection – occasionally used for painful bursitis overlying an exostosis.

Lifestyle & Activity Modifications

• Avoid high‑impact activities that compress the lesion (e.g., long‑distance running for a tibial exostosis).
• Wear protective padding or custom orthotics if the growth rubs against footwear.
• Maintain a healthy weight to reduce mechanical stress on affected joints.

Living with Exostoses (Osteochondroma)

Daily Management Tips

• Self‑monitoring – feel the lesion regularly for any change in size, firmness, or tenderness.
• Protective gear – padded sleeves, knee pads, or shoe inserts can prevent irritation.
• Exercise – low‑impact activities (swimming, cycling) maintain fitness without excessive joint stress.
• Skin care – keep the skin over the bump clean and dry; apply barrier creams if friction occurs.
• Regular follow‑up – schedule appointments every 12–18 months until growth plates close, then every 2–3 years if lesions remain.
• Family planning (for HME) – discuss genetic counseling if you carry an EXT mutation.

Psychosocial Considerations

Visible or multiple lesions can affect self‑esteem, especially in teenagers. Support groups (e.g., HME Foundation) and counseling can help patients cope with body image concerns.

Prevention

Because most osteochondromas are congenital or genetic, primary prevention is limited. However, the following measures can reduce secondary complications:

• Early detection in families with HME through genetic testing and routine radiographs.
• Protective equipment during sports to avoid traumatic irritation of existing lesions.
• Prompt treatment of bursitis or skin breakdown to prevent infection.

Complications

Untreated or unmonitored exostoses may lead to:

• Mechanical irritation – chronic pain, bursitis, or skin ulceration.
• Neurovascular compression – numbness, weakness, or vascular insufficiency.
• Fracture of the stalk – can cause sudden severe pain and may require surgical fixation.
• Malignant transformation – estimated at 1–4 % for solitary lesions and 5–25 % for those with HME; typically progresses to low‑grade chondrosarcoma.<sup>[3] NIH</sup>
• Joint deformity – especially when lesions are near the growth plate, leading to angular deformities (e.g., genu valgum).

When to Seek Emergency Care

---

Sources: [1] Mayo Clinic. Osteochondroma. May 2023. [2] World Health Organization. Classification of Tumours of Soft Tissue and Bone, 5th ed., 2020. [3] National Institutes of Health. Genetics Home Reference – Hereditary Multiple Exostoses. 2022. [4] Cleveland Clinic. Osteochondroma (Exostosis) – Symptoms & Treatment. 2023. [5] American Academy of Orthopaedic Surgeons. Management of Benign Bone Tumors. 2022.

```